Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia
Open Access
- 1 June 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 4 (6) , 865-875
Abstract
An early interventional effort in oral premalignancy requires novel molecular targets and diagnostic biomarkers to delay or reverse incidences of malignant progression. Microarray-based transcriptional profiling in disease states provides global insight into the causal biomolecular processes and novel pathways involved. In this study, we investigated transcript profiles in precancerous oral lesions to identify nearly 1,700 genes as significantly overexpressed or underexpressed and a primarily affected metabolic pathway that may be responsible for irreversible transition to progressive stages of oral cancer. For the first time, we show a convergence of several genes and pathways known for their oncogenic capabilities, in progression of premalignant oral epithelial tissues. This study consequently provides a molecular basis for persistent proinflammatory conditions in oral premalignant tissues. We found that lipocalin-type prostaglandin D2 synthase (PTGDS), a key enzyme in the arachidonic acid metabolism pathway, as repressed in premalignant stages. We show the protective role of these enzyme-derived metabolites in inhibiting cell proliferation using an in vitro oral cancer progression model. We have also confirmed the overexpression of two invasion-related biomarkers, psoriasin (PSOR1) and versican (CSPG2), in oral premalignant and malignant archival tissues. Our results clearly indicate that pharmacologic intervention with anti-inflammatory prostaglandin D2–like analogues may help prevent or delay oral epithelial carcinogenesis because of metabolic restoration of a negative feedback regulatory loop through its several cognate receptors or target molecules. Further studies directed toward a multitude of possible protective mechanisms of this lipocalin-type enzyme or its products in oral cancer progression are warranted.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for ChemopreventionJournal of Clinical Oncology, 2005
- Global gene expression profiles of human head and neck squamous carcinoma cell linesInternational Journal of Cancer, 2004
- Expression of prostaglandin D2 receptors DP1 and DP2 by human colorectal cancer cellsCancer Letters, 2004
- Transcriptional expression profiles of oral squamous cell carcinomasCancer, 2002
- 15-Deoxy-Δ12,14-prostaglandin J2Journal of Biological Chemistry, 2002
- Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysisOncogene, 2001
- Inhibition of Cellular Proliferation through IκB Kinase-Independent and Peroxisome Proliferator-Activated Receptor γ-Dependent Repression of Cyclin D1Molecular and Cellular Biology, 2001
- Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arraysOncogene, 2000
- Head and Neck CancerNew England Journal of Medicine, 1993
- Evaluation of glucocorticoid‐induced DNA fragmentation in mouse thymocytes by flow cytometryCell Proliferation, 1991